Finding may herald emergence of pan–drug-resistant bugs
Probuphine provides low-level buprenorphine for six months
First recombinant factor VIII single-chain therapy
Manufacturing issues sink ZS-9 application
Class-action complaint alleges misrepresentation, false advertising
Publication outlines implementation strategies in acute care
Approval decision expected in July
If approved, drug would be first single-dose oral therapy for BV

P&T May 2016
Table of Contents


Editor’s Memo
Although the death rate from cancer has fallen in recent years, progress against these diseases is uneven. This issue focuses on research efforts to find treatments.
The Obama administration has announced a drive to cure cancer, although the mission has been under way for decades. How are researchers doing, and what is in store?


Medication Errors
We must ensure safer use of oral chemotherapy
Prescription: Washington
CMS stands pat on exchange formulary standards
Approvals, new indications, regulatory activities, and more
Coagulation factor IX (recombinant), albumin fusion protein (Idelvion) for hemophilia B; captisol-enabled melphalan hydrochloride (Evomela) for multiple myeloma; and antihemophilic factor (recombinant) (Kovaltry) for hemophilia A
Meeting Highlights
Key sessions at HemOnc Today covered systemic and locoregional use of immunotherapies. At the cardiology meeting, preventive strategies took center stage.